A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjectsGuangwen Liu, Haimiao Yang, Yingzi Cui et al.|Expert Opinion on Biological Therapy|2021Cited by 5
Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjectsZhengzhi Liu, Haimiao Yang, Jinling Xue et al.|Naunyn-Schmiedeberg s Archives of Pharmacology|2024Cited by 2
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjectsZhengzhi Liu, Haimiao Yang, Zhenyue Gao et al.|Expert Opinion on Drug Metabolism & Toxicology|2022Cited by 0